FDA's new Guidance Documents for 2012
The U.S. Food and Drug Administration FDA has issued its yearly list of planned draft and final guidance documents for 2012. There are about 50 such guidance documents planned.
This is an overview about some important ones:
Biopharmaceutics and Biosimilarity:
- Scientific Considerations in Demonstrating Biosimilarity To a Reference Product
- Quality Considerations in Demonstrating Biosimilarity To a Reference Protein Product
Combination Products:
- Development of Drugs in Combination
cGMPs and Compliance:
- Control of Highly Potent Compounds
- Importation of Active Pharmaceutical Ingredients (API) for Use in Human Drugs
Labeling, Packaging and Supply Chain:
- Securing the Drug Supply Chain-Standards for Tracking and Tracing Prescription Drug Packages
- Pediatric Information: Incorporating into Human Prescription Drug and Biological Products Labeling
Source: FDA Guidance Agenda
Compiled by
Wolfgang Schmitt
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
10.02.2025Is "right-sizing" GMP and Compliance (Lean GMP) possible?
10.02.2025Update of Training Material for ICH Q8, Q9 and Q10
05.02.2025European Shortages Monitoring Platform (ESMP) goes live
05.02.2025The ICH Q9 Briefing Package - a Forgotten Document?
23.01.2025FDA proposes Standardized Testing for Asbestos in Talc-Containing Cosmetic Products
16.01.20252nd Version of the Union list of Critical Medicines published